Edwards Lifesciences (EW -5.4%)
slips on average volume in apparent response to a Jefferies report of a
“sharp step down” last month in the growth of heart valve replacements.
Hospital purchasing data for December showed
growth ranging from -2% to +3% for transcatheter aortic valve
replacement (TAVR) procedures compared to 27-28% growth in October and
November. Jefferies cautions over reading too much into one month due to
lags in data reporting and the lack of new sites in the same-store
sales model.
The company is scheduled to report Q4 results after the close on Thursday, January 30.
https://seekingalpha.com/news/3534028-edwards-lifesciences-down-5-on-recent-drop-in-heart-valve-replacements
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.